The unique flexibility of our internally developed pipeline drives the potential for novel and differentiated combination therapies. We’re building on our legacy of innovation with a deep understanding of cancer biology and the immune system. When it comes to targeting diseases like cancer, we’re ...
REGN has a deep pipeline with many promising candidates: itepekimab (IL-33) for COPD, fianlimab (LAG3) for melanoma, and linvoseltamab (BCMAxCD3) for multiple myeloma. The BLA for linvoseltamab was resubmitted after the resolution of third-party manufacturing issues, with the launch anticipat...
Explore Regeneron’s pipeline of investigational medicines advancing through clinical trials for a range of serious diseases.
Inc. (NASDAQ: REGN) today announced new and updated data from its hematology pipeline will be shared across 23 abstracts at the American Society of Hematology (ASH) 2024 Annual Meeting, taking place from December 7-10 in...
TARRYTOWN, N.Y.,Jan. 13, 2025(GLOBE NEWSWIRE) --Regeneron Pharmaceuticals, Inc.(NASDAQ: REGN) today will share corporate progress and highlights from the Company’s broad and diverse investigational pipeline while presenting at the annualJ.P. Morgan Healthcare Conference. The presentation...
"Our thesis is that REGN’s financial growth will accelerate in 2026, its pipeline will advance, and the P/E multiple will expand," he wrote. Regeneron's 2024 Q4 financial results, released Tuesday,beat on both lines. More on Regeneron Pharmaceuticals ...
Zacks Equity Research
Updates from the clinical pipeline include: EYLEA HD (aflibercept) 8 mg The Company announced positive three-year (156-week) data from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema (DME). At three years, the longer-term data showed t...
Pipeline DA-NET Prices T&Ds Alerts Results REGENERON: DA-NETDA-NET is the ratio of cumulative 5-year net profit over the current day market cap, expressed as a premium/discount to the ratio of our global sector universe. The five year net profit window is forwards looking and typ...
Regeneron's strong Q2 earnings show continued growth, with Dupixent leading the way. Learn why I'm maintaining a Buy rating on REGN stock.